The Institute of Hematology and Transfusion Medicine (IHTM) in Warsaw has produced autologous serum eye drops (ASEDs) for the treatment of Dry Eye Syndrome (DES) since 1991. In 2019, IHTM introduced allogeneic tears (alloSEDs) for patients on long-term treatment. 114 patients who applied alloSEDs were included in the study.They were asked to complete the OSDI questionnaire before and after using ASEDs and 100 units of alloSEDs drops from each donation. The OSDI index rates DES severity (0 no symptoms; 100 severe). We also compared the content of IL-1β, IL-2, IL- 6, IL-10 and VEGF in ASEDs (38 samples) and alloSEDs (15 serum samples). The study data covered the 2019–2022 period. 114 patients participated in the study. We compared the the effectiveness of ASEDs and alloSEDs. The average, OSDI dropped from 68.42 ± 5,86 (before application) to 51.05 ± 19,06 (after application). Data from the questionnaires (prepared at IHTM) completed and returned (41/114) present the most common indications for the use of serum drops, including DES with no underlying disease, DES secondary to GvHD (Graft versus Host Disease), Sjögren's Syndrome (SS). The study reported higher cytokine levels associated with disease entities such as SS. After application of drops with high cytokine levels, patients reported adverse reactions such as sand under the eyelids, impaired visual acuity, and worse eye lubrication. AlloSEDs with acceptably low values of pro-inflammatory cytokines and sufficiently high levels of VEGF growth factor may contribute to alleviation of inflammatory eye symptoms.

中文翻译：

---

血清细胞因子水平与同种异体血清滴眼液效果的相关性


华沙血液学和输血医学研究所 (IHTM) 自 1991 年以来一直生产用于治疗干眼综合症 (DES) 的自体血清滴眼液 (ASED)。2019 年，IHTM 为长期接受治疗的患者推出同种异体泪液 (alloSED)治疗。该研究纳入了 114 名使用 alloSED 的患者。他们被要求在使用 ASED 之前和之后填写 OSDI 调查问卷，并从每次捐赠中滴下 100 单位的 alloSED。 OSDI 指数对 DES 严重程度进行评级（0 为无症状；100 为严重）。我们还比较了ASED（38个样本）和alloSED（15个血清样本）中IL-1β、IL-2、IL-6、IL-10和VEGF的含量。研究数据涵盖2019-2022年期间。 114 名患者参与了该研究。我们比较了 ASED 和 alloSED 的有效性。 OSDI 平均值从 68.42 ± 5,86（应用前）下降至 51.05 ± 19,06（应用后）。完成并返回的调查问卷（在 IHTM 准备）中的数据 (41/114) 显示了使用血清滴剂的最常见适应症，包括无基础疾病的 DES、继发于 GvHD（移植物抗宿主病）的 DES、干燥综合征（ SS）。该研究报告称，较高的细胞因子水平与 SS 等疾病相关。在使用高细胞因子水平的滴剂后，患者报告了不良反应，例如眼睑下有沙子、视力受损和眼睛润滑状况恶化。 AlloSED 具有可接受的低促炎细胞因子值和足够高水平的 VEGF 生长因子，可能有助于缓解眼部炎症症状。